CVI Holdings’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

CVI Holdings’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-83,333	Closed	-$43K	–	956
2021 Q4	$43K	Hold	83,333	–	–	﹤0.01%	805
2021 Q3	$68K	Hold	83,333	–	–	﹤0.01%	707
2021 Q2	$85K	Hold	83,333	–	–	0.01%	625
2021 Q1	$92K	Buy	+83,333	New	+$150K	0.01%	490

Other funds holding TLSIW

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

CVI Holdings's TLSIW Position: Q1 2022 in Review

CVI Holdings sold out of TriSalus Life Sciences Warrant (TLSIW) in Q1 2022, closing a stake of 83,333 shares — an estimated $43K sold.

CVI Holdings first reported a position in TLSIW in Q1 2021 and held it in 4 quarters. The position peaked at $92K in Q1 2021. 26 funds tracked by Wall St. Rank hold TLSIW as of Q1 2022.

CVI Holdings reported no remaining TriSalus Life Sciences Warrant position as of Q1 2022 after selling out during the quarter.
CVI Holdings sold 83,333 TriSalus Life Sciences Warrant shares in Q1 2022, an estimated $43K.
CVI Holdings first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 4 quarters.
CVI Holdings's TriSalus Life Sciences Warrant position peaked at $92K in Q1 2021.
26 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2022.

Based on CVI Holdings's 13F filing for Q1 2022, filed 16 May 2022.